Fuji 
SAA sponsors and develops the first extensive survey among AS patients nationwide. The AS Life Impact Survey results in major findings never before documented that enable physicians and SAA to better address the needs of the AS community.
The organization helps organize a meeting with the European research group ASAS, U.S. Food and Drug Administration (FDA) researchers, and pharmaceutical companies, to draft an FDA guidance document on AS drug research and development.
